Recurrent Adult Immunoblastic Large Cell Lymphoma Terminated Phase 1 Trials for Vorinostat (DB02546)

IndicationStatusPhase
DBCOND0028500 (Recurrent Adult Immunoblastic Large Cell Lymphoma)Terminated1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01116154Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin LymphomaTreatment